A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis

Journal of Crohn's and Colitis

Volumn 5, Issue 2, 2011, Pages 115-121

  Wildt, Signe ^a   Nordgaard, Inge ^a   Hansen, Ulla ^a   Brockmann, Elke ^b   Rumessen, Jüri J ^c  

^a HVIDOVRE HOSPITAL   (Denmark)

^b CHR HANSEN A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Lactobacteria; Maintenance of remission; Probiotics; Ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; PLACEBO; PROBIO TEC AB 25; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; BIFIDOBACTERIUM ANIMALIS LACTIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACTOBACILLUS ACIDOPHILUS; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; ULCERATIVE COLITIS;

ADULT; AGED; BIFIDOBACTERIUM; COLITIS, ULCERATIVE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; PROBIOTICS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953069242     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.11.004     Document Type: Article

References (26)

1. d'Hans G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., Léman M., Marteau P., Rutgeerts P., Schölmerich J., Sutherland L.R. Clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786. Ref Type: Abstract.
2. Sutherland L., Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, CD000544.
3. Gisbert J.P., Linares P.M., McNicholl A.G., Mate J., Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009, 30:126-137.
4. Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, CD000478.
5. Fuller R. Probiotics in human medicine. Gut 1991, 32:439-442.
6. Tursi A., Brandimarte G., Giorgetti G.M., Forti G., Modeo M.E., Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004, 10:I126-I131.
7. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354:635-639.
8. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
9. Zocco M.A., dal Verme L.Z., Cremonini F., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:1567-1574.
10. Shanahan F., Guarner F., Wright A.V., Vilpponen-Salmala T., O'Donoghue D., Kiely B. A one year, randomised double-blind, placebo controlled trial of a Lactobacillus or a Bifidobacteria probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006, 130. Progid Investigators, Ref Type: Abstract.
11. Jowett S.L., Seal C.J., Phillips E., Gregory W., Barton J.R., Welfare M.R. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003, 38:164-171.
12. Walmsley R.S., Ayres R.C., Pounder R.E., Allan R.N. A simple clinical colitis activity index. Gut 1998, 43:29-32.
13. Baron J.H., Connell A.M., Lenard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964, 1:89-92.
14. Truelove S.C., Richards W.C. Biopsy studies in ulcerative colitis. Br Med J 1956, 1:1315-1318.
15. Taipale T., Pienihäkkinen K., Isolauri E., Nexmann-Larsen C., Brockmann E., Alanen P., Jokela J., Söderling E. Bifidobacterium animalis subsp. lactis BB-12 delivered with a novel pacifier may reduce the risk of respiratory infections in breastfed children. Submitted Br J Nutr 2010 Sep, 24:1-7. (Epub ahead of print).
16. Hoier E. Saure-und gallentoleranz von lactobacillus acidophilus and bifidobakterien. Lebenmittlindustrie Milchwirtschaft 1992, 26:769-772.
17. Alander M., Mättö J., Kneifel W., et al. Effect of galacto-oligosaccharide supplementation on human faecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract. Int Dairy J 2001, 11:817-825.
18. Fukushima Y., Kawata Y., Hara H., Terada A., Mitsuoka T. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998, 42:39-44.
19. Ouwehand A.C., Salminen S., Tölkkö S., Roberts P., Ovaska J., Salminen E. Resected human colonic tissue: new model for characterizing adhesion of lactic acid bacteria. Clin Diagn Lab Immunol 2002, 184-186.
20. Hatcher G.E., Lambrecht R.S. Augmentation of macrophage phagocytic activity by cell-free extracts of selected lactic acid-producing bacteria. J Dairy Sci 1992, 76:2485-2492.
21. Miettinen M., Vuopio-Varkila J., Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996, 64:5403-5405.
22. Sood A., Midha V., Makharia G.K., et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:1202-1209. 1209.
23. Van Niel C.W., Feudtner C., Garrison M.M., Christakis D.A. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002, 109:678-684.
24. Kruis W., Schutz E., Fric P., Fixa B., Judmaier G., Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11:853-858.
25. Fedorak R.N., Dieleman L.A. Probiotics in the treatment of human inflammatory bowel diseases: update 2008. J Clin Gastroenterol 2008, 42(Suppl 2):S97-S103.
26. Cui H.H., Chen C.L., Wang J.D., et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 2004, 10:1521-1525.